Scholarlink

Background <p>Impact of frailty on prognosis in patients with metastatic and non-metastatic colorectal cancer (CRC) was studied.</p> Methods <p>Patients aged ≥60 years with CRC were identified in Nationwide Inpatient Sample database and analyzed retrospectively. Frailty was defined when Hospital Frailty Risk Score ≥5. Patients were grouped and matched by metastatic status. Logistic and linear regression were used to assess association between frailty and in-hospital outcomes.</p> Results <p>After matching, 99,017 metastatic and 418,435 non-metastatic CRC were included. Frailty was significantly associated with increased in-hospital mortality (metastatic: OR = 1.10, 95% CI 1.05–1.17; non-metastatic: aOR = 1.05, 95% CI 1.00–1.10), prolonged length of stay (metastatic: OR = 1.30, 95% CI 1.26–1.34; non-metastatic: aOR = 1.37, 95% CI 1.34–1.39), and discharge to long-term care (metastatic: OR = 1.67, 95% CI 1.62–1.73; non-metastatic: aOR = 2.10, 95% CI 2.07–2.14). Frailty was also associated with higher total hospital costs, with additional $3,750 (95% CI $2940–$4560) in metastatic CRC and $1920 (95% CI $1480–$2360) in non-metastatic CRC.</p> Conclusions <p>Frailty is an independent predictor of adverse outcomes among older patients with CRC, regardless of metastatic status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The association between hospital frailty risk score and adverse inpatient outcomes in older adults with colorectal cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月6日

查看全文
  • Hao-Tsai Cheng,
  • Chen-June Seak,
  • Ching-Yi Cheng,
  • Shu-Wei Huang,
  • Chang-Mu Sung,
  • Tsung-Hsing Chen

摘要

Background

Impact of frailty on prognosis in patients with metastatic and non-metastatic colorectal cancer (CRC) was studied.

Methods

Patients aged ≥60 years with CRC were identified in Nationwide Inpatient Sample database and analyzed retrospectively. Frailty was defined when Hospital Frailty Risk Score ≥5. Patients were grouped and matched by metastatic status. Logistic and linear regression were used to assess association between frailty and in-hospital outcomes.

Results

After matching, 99,017 metastatic and 418,435 non-metastatic CRC were included. Frailty was significantly associated with increased in-hospital mortality (metastatic: OR = 1.10, 95% CI 1.05–1.17; non-metastatic: aOR = 1.05, 95% CI 1.00–1.10), prolonged length of stay (metastatic: OR = 1.30, 95% CI 1.26–1.34; non-metastatic: aOR = 1.37, 95% CI 1.34–1.39), and discharge to long-term care (metastatic: OR = 1.67, 95% CI 1.62–1.73; non-metastatic: aOR = 2.10, 95% CI 2.07–2.14). Frailty was also associated with higher total hospital costs, with additional $3,750 (95% CI $2940–$4560) in metastatic CRC and $1920 (95% CI $1480–$2360) in non-metastatic CRC.

Conclusions

Frailty is an independent predictor of adverse outcomes among older patients with CRC, regardless of metastatic status.